OncoMatch/Clinical Trials/NCT07833085
CAIX-targeted PET/CT in Solid Tumors
Official title: Carbonic Anhydrase IX-targeted PET/CT Imaging for Detecting Solid Tumors
Is NCT07833085 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for malignant solid tumors.
Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Renal Cell Carcinoma
Non-Small Cell Lung Carcinoma
Breast Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07833085 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify